VTAK Showcases Innovation at EHRA 2026 with LockeT and VIVO Spotlighted
EHRA 2026 Attendance Marks First Major European Event Since LockeT CE Mark
Catheter Precision (NYSE: VTAK) has announced that it will attend the annual European Heart Rhythm Association (EHRA) conference in Paris from April 12-14, 2026. This marks the company’s first appearance at a large European event since receiving the CE Mark approval for its LockeT suture retention device. The conference provides a key platform for Catheter Precision to meet with European physicians, distributors, and thought leaders in electrophysiology as it expands its presence in the region.
LockeT Device Gains International Visibility Following CE Mark Approval
The LockeT is a Class 1 suture retention device registered with the FDA and now CE Marked, making it available for use across European markets. According to CEO David Jenkins, the EHRA conference serves as an ideal venue to educate new physicians and distributors about LockeT’s wound closure innovation—aimed at improving outcomes after percutaneous venous punctures. This milestone not only strengthens Catheter Precision’s international reputation but also accelerates adoption among specialized healthcare professionals.
VIVO 3D Imaging System Enhances Cardiac Arrhythmia Procedures
In addition to LockeT, Catheter Precision is highlighting its VIVO™ system, which enables non-invasive 3D mapping to quickly identify the origins of ventricular arrhythmias. VIVO is both FDA-cleared and CE Marked, streamlining the workflows for cardiac arrhythmia interventions and potentially reducing overall procedure times—a point of focus for global providers looking to boost efficiency and patient outcomes.
Key Product Details for EHRA 2026
| Product | Regulatory Status | Application |
|---|---|---|
| LockeT | FDA Registered, CE Marked | Suture retention after venous puncture |
| VIVO™ | FDA Cleared, CE Marked | 3D imaging for ventricular arrhythmia mapping |
Strategic Emphasis on Physician Education and Global Expansion
Jenkins emphasizes that conferences like EHRA remain a top priority for fostering relationships with key opinion leaders and introducing innovative solutions directly to the practitioners who use them. With the CE Mark providing new access to European markets, Catheter Precision’s participation in EHRA signals an ongoing push toward international expansion and market penetration.
Takeaway: VTAK Leverages Global Events to Accelerate Adoption
While the full impact of Catheter Precision’s European expansion will unfold over time, the combination of regulatory achievements and proactive physician engagement suggests continued momentum for its product pipeline. Investors and healthcare professionals might watch future updates from VTAK for additional signals of market adoption and product traction across Europe.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI